Loss of LDOC1 expression by promoter methylation in cervical cancer cells

Cancer Investigation

Volumn 31, Issue 9, 2013, Pages 571-577

  Buchholtz, Marie Luise ^a   Jückstock, Julia ^a   Weber, Elena ^a   Mylonas, Ioannis ^a   Dian, Darius ^a   Brüning, Ansgar ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cervical cancer; Epigenetics; LDOC1; Promoter methylation; Tumor suppressor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUCINE ZIPPER DOWNREGULATED IN CANCER 1 GENE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

BIOPSY; CELL DEATH; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELA CELLS; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84887234428     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.845671     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J,Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Available from: http://seer. cancer. gov/statfacts/html/cervix. html; June 2013.
3. Available from: http://globocan. iarc. fr/factsheets/cancers/cervix. asp; June 2013.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/ Latinos, 2012. CA Cancer J Clin 2012;62:283-298.
5. Alfonso Duenas-Gonźalez A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 2005;4:38.
6. Peltom̈aki P. Mutations and epimutations in the origin of cancer. Exp Cell Res 2012;318:299-310.
7. Lu Q, Ma D, Zhao S. DNA methylation changes in cervical cancers. Methods Mol Biol 2012;863:155-176.
8. Nagasaki K, Manabe T, Hanzawa H, Maass N, Tsukada T, Yamaguchi K. Identification of a novel gene, LDOC1, down-regulated in cancer cell lines. Cancer Lett 1999;140:227-234.
9. Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Mori Y, Mori R, Tomoda K, Katada T, Harada K, Fujii Y. Identification of candidate genes involved in the radiosensitivity of esophageal cancer cells by microarray analysis. Dis Esophagus 2008;21: 288-297.
10. Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O'Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood 2011;117:4076-4084.
11. Lee CH, Wong TS, Chan JY, Lu SC, Lin P, Cheng AJ, Chen YJ, Chang JS, Hsiao SH, Leu YW, Li CI, Hsiao JR, Chang JY. Epigenetic regulation of the X-linked tumor suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. J Pathol 2013;230:298-309.
12. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM, Clark RA, Schwartz S, Segraves R, Oseroff VV, Albertson DG, Pinkel D, Eichler EE. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 2005;77:78-88.
13. Kouprina N, Pavlicek A, Noskov VN, Solomon G, Otstot J, Isaacs W, Carpten JD, Trent JM, Schleutker J, Barrett JC, Jurka J, Larionov V. Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res 2005;15:1477-1486.
14. Br̈uning A, Vogel M, Burger P, Rahmeh M, Gingelmaier A, Friese K, Lenhard M, Burges A. Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells. Biochem Biophys Res Commun 2008;377:1309-1314.
15. Br̈uning A. Analysis of nelfinavir-induced endoplasmic reticulum stress. Methods Enzymol 2011;491:127-142.
16. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-1108.
17. Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Br̈uning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther 2008;7:1460-1467.
18. Inoue M, Takahashi K, Niide O, Shibata M, Fukuzawa M, Ra C. LDOC1, a novel MZF-1-interacting protein, induces apoptosis. FEBS Lett 2005;579:604-608.
19. Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-764.
20. L̈of-̈ Ohlin ZM, Sorbe B, Wingren S, Nilsson TK. Hypermethylation of promoter regions of the APC1A and p16INK4a genes in relation to prognosis and tumor characteristics in cervical cancer patients. Int J Oncol 2011;39:683-688.
21. Sobti RC, Singh N, Hussain S, Suri V, Nijhawan R, Bharti AC, Bharadwaj M, Das BC. Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. Cell Oncol 2011;34:533-543.
22. Salemi M, Giuffrida D, Giuffrida MC, Soma PF, Rolfo A, Cimino L, Condorelli RA, Castiglione R, La Vignera S, Calogero AE. LDOC1 gene expression in two patients with head and neck squamous cell carcinomas and Parkinson's disease. Tumori 2012;98:86e-88e.
23. Salemi M, Soma PF, Bosco P, Vicari E, Roberto C, Calogero AE. CASP3 and LDOC-1 gene expression in a patient with carcinoma in the hairy part of the head skin and Alzheimer disease. Hum Cell 2013;26:128-130.
24. Mizutani K, Koike D, Suetsugu S, Takenawa T. WAVE3 functions as a negative regulator of LDOC1. J Biochem 2005;138:639-646.
25. Chih DY, Park DJ, Gross M, Idos G, Vuong PT, Hirama T, Chumakov AM, Said J, Koeffler HP. Protein partners of C/EBPepsilon. Exp Hematol 2004;32:1173-1181.
26. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 2010;336:25-37.
27. Baldwin AS. Regulation of cell death and autophagy by IKK and NF-?B: critical mechanisms in immune function and cancer. Immunol Rev 2012;246:327-345.
28. Roossink F, de Jong S, Wisman GB, van der Zee AG, Schuuring E. DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art. Cell Oncol 2012;35:231-241.